
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals Inc. has demonstrated robust cash inflows, which enable further deal-making and enhance its compounding business model, positioning the company advantageously within the smid-cap biotech sector. With anticipated strong product launches for Filspari and Ohtuvayre, along with ongoing revenue growth from stable contributors, the company's financial outlook appears promising. Additionally, Ligand's revenue streams from royalties, license payments, and sales of Captisol material bolster its financial stability and growth potential.
Bears say
The financial outlook for Ligand Pharmaceuticals is concerning due to several fundamental issues, including the potential underperformance of royalty assets and challenges related to the intellectual property durability of key products. Additionally, uncertainties surrounding the approval of clinical-stage royalty assets, less favorable future terms, and unexpected challenges faced by commercial partners contribute to a negative overall assessment. The company's recent model updates, which reflect incrementally lower net cash and a reduced weighted average cost of capital, further highlight these financial pressures.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares